window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

clinical trial

  • Advanced Therapies,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma

    Enterome Phase 1/2 data show EO2463-induced CD8 T-cell expansion was [...]

    July 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer

    Telix has dosed the first patient in a Phase 3 [...]

    July 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Medicus receives FDA feedback and IRB approval for Teverelix Phase 2 urinary retention trial

    Medicus Pharma has received positive feedback from FDA and central [...]

    July 20, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data

    Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]

    July 14, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Q32 Bio reports positive Phase 2 alopecia areata trial results for bempikibart

    Q32 Bio has reported positive 36-week Phase 2 data showing [...]

    July 13, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg Pharma doses first patient in POLB 001 trial to prevent cytokine release syndrome

    Poolbeg Pharma has dosed the first patient in a clinical [...]

    July 13, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    FORE Biotherapeutics completes enrolment in registrational plixorafenib brain tumour study

    FORE Biotherapeutics has completed target enrolment in the primary central [...]

    July 8, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression

    Compass Pathways has reported positive six-month results from its second [...]

    July 8, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Research & Development,Therapeutic Areas

    EnteroBiotix doses first patient in Phase 2b IBS-C microbiome trial

    EnteroBiotix has dosed the first patient in its Phase 2b [...]

    July 7, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Grifols doses first patient in Phase 3 alpha-1 therapy trial

    Grifols has dosed the first participant in a Phase 3 [...]

    July 2, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Natus expands AI-powered EEG analysis across Europe
    Categories: Central Nervous System, Digital & Data, Medical devices
  • Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma
    Categories: Advanced Therapies, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top